Fig. 2. Synthesis and evaluation of a series of BCL-xL and/or BCL-2 degraders.
a The structure of the BCL-xL and/or BCL-2 degraders (racemic mixture). b The BCL-xL and BCL-2 degradation profiling of the PROTACs evaluated in 293T cells after the cells were treated with four different concentrations of indicated PROTACs for 16 h. The DC50 and Dmax were calculated using Prism based on the ImageJ-quantified western blots in Supplementary Fig. 4. c, d AlphaLISA assay to determine the formation of BCL-xL/PROTAC/VHL-ELOC-ELOB (VCB) (c) or BCL-2/PROTAC/VCB (d) ternary complex in a cell-free condition. Data represent the mean of a single experiment with 2 technical replicates. Similar results were obtained in one more independent experiment. e, f NanoBRET assays evaluating intracellular BCL-xL/PROTAC/VCB (e) or BCL-2/PROTAC/VCB (f) ternary complex formation. 293T cells were transiently transfected with HiBit-BCL-xL, LgBit, and HaloTag-VHL or HiBit-BCL-2, LgBit, and HaloTag-VHL and then treated with a serial dilution of the indicated compounds for 6 h. Data are expressed as mean ± s.e.m. of three biological replicates. Source data are provided as a Source data file.